Home » Stocks » Castle Biosciences

Castle Biosciences, Inc. (CSTL)

Stock Price: $41.99 USD 1.11 (2.72%)
Updated Jul 8, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 812.93M
Revenue (ttm) 60.57M
Net Income (ttm) 7.20M
Shares Out 19.36M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 8, 2020
Last Price $41.99
Previous Close $40.88
Change ($) 1.11
Change (%) 2.72%
Day's Open 41.20
Day's Range 40.84 - 42.21
Day's Volume 147,816
52-Week Range 15.26 - 44.53

More Stats

Market Cap 812.93M
Enterprise Value 739.62M
Earnings Date (est) Sep 8, 2020
Ex-Dividend Date n/a
Shares Outstanding 19.36M
Float 10.57M
EPS (basic) -0.41
EPS (diluted) -0.21
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.27M
Short Ratio 8.01
Short % of Float 13.95%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 13.42
PB Ratio 8.61
Revenue 60.57M
Operating Income 8.69M
Net Income 7.20M
Free Cash Flow n/a
Net Cash 73.31M
Net Cash / Share 3.79
Gross Margin 73.56%
Operating Margin 14.34%
Profit Margin 9.70%
FCF Margin n/a
ROA 7.18%
ROE 16.94%
ROIC 35.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

(5.38% upside)
Current: 41.99
Target: 44.25
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth127.62%65.67%-
Gross Profit44.5617.498.83
Operating Income7.33-3.84-10.90
Net Income5.28-6.37-12.37
Shares Outstanding8.581.911.90
Earnings Per Share-0.21-5.33-8.08
Operating Cash Flow7.02-12.30-12.23
Capital Expenditures-0.94-0.28-0.49
Free Cash Flow6.08-12.57-12.73
Cash & Equivalents98.854.481.21
Total Debt25.1224.5018.60
Net Cash / Debt73.72-20.02-17.39
Book Value85.11-56.57-50.31
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Castle Biosciences, Inc.
Country United States
Employees 133
CEO Derek J. Maetzold

Stock Information

Ticker Symbol CSTL
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: CSTL


Castle Biosciences, Inc., a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; and two late-stage proprietary products in development, which address cutaneous squamous cell carcinoma and suspicious pigmented lesions, which are indications with high clinical need in dermatological cancer. It offers test services through physicians, physician assistants, and nurse practitioners. The company was founded in 2007 and is headquartered in Friendswood, Texas.